AT
ART-TG (Inserm US35) at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
ART-TG (Inserm US35) brings 2 presentations to ESGCT 2026 in Hamburg. Its work covers taking lentiviral gene therapy from process to clinic. One line scales up industrial production of a TREM2 lentiviral vector, and another evaluates the safety and biodistribution of a dual-function vector for sickle cell disease.
| Organization | ESGCT 2026 Attendance |
|---|---|
AT ART-TG (Inserm US35) Corbeil-Essonnes, France | |
Inserm translational gene therapy unit developing lentiviral vector processes, analytical methods and engineered blood and immune cells for clinical use. | Chair Tue Oct 27 11:15am–1:00pm EDUCATION SESSION 2b - Expanding GT models for mechanisms, prediction and data analysis Clinical trials and translation Poster Wed Oct 28 1:30pm–3:30pm Development of an industrial process for the production of the TREM2 lentiviral vector Poster Wed Oct 28 1:30pm–3:30pm Preclinical evaluation of the in vivo biosafety and biodistribution of a novel bi-functional lentiviral vector for the gene therapy of sickle cell disease. |
Instantly find 20 buyers from ART-TG (Inserm US35)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction